Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1972 Apr;1(4):354–357. doi: 10.1128/aac.1.4.354

Susceptibility of Herpesviruses to Cytosine Arabinoside: Standardization of Susceptibility Test Procedure and Relative Resistance of Herpes Simplex Type 2 Strains

Milan Fiala 1, Anthony Chow 2, Lucien B Guze 3
PMCID: PMC444221  PMID: 4364937

Abstract

Susceptibility testing of herpes simplex type 1 (HSV-1) and type 2 (HSV-2) viruses to cytosine arabinoside (Ara-C) has been standardized under conditions of optimal reproducibility, susceptibility, and simplicity. Standard conditions were defined as virus inoculum of 101.5 to 102.5 TCID50, WI-38 strain of lung fibroblasts, 2-day incubation, and observation of virus cytopathic effect after staining by the May-Greenwald-Giemsa method. The variability of minimum inhibitory concentration (MIC) of cytopathic effect was fourfold within each test and sixfold in successive assays. MIC values of all seven tested HSV-1 strains were in the range of 0.25 to 0.75 μg per ml, whereas four of nine HSV-2 strains had MIC values of 0.9 μg per ml and greater. A similar method can be used for assay of virus inhibitory titers of body fluids.

Full text

PDF
354

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BUTHALA D. A. CELL CULTURE STUDIES ON ANTIVIRAL AGENTS. I. ACTION OF CYTOSINE ARABINOSIDE AND SOME COMPARISONS WITH 5-IODO-2-DEOXYURIDINE. Proc Soc Exp Biol Med. 1964 Jan;115:69–77. doi: 10.3181/00379727-115-28834. [DOI] [PubMed] [Google Scholar]
  2. Chow A. W., Foerster J., Hryniuk W. Cytosine arabinoside therapy for herpesvirus infections. Antimicrob Agents Chemother (Bethesda) 1970;10:214–217. [PubMed] [Google Scholar]
  3. Juel-Jensen B. E. Severe generalized primary herpes treated with cytarabine. Br Med J. 1970 Apr 18;2(5702):154–155. doi: 10.1136/bmj.2.5702.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Juel-Jensen B. E. Varicella and cytosine arabinoside. Lancet. 1970 Mar 14;1(7646):572–572. doi: 10.1016/s0140-6736(70)90815-9. [DOI] [PubMed] [Google Scholar]
  5. Lowry S. P., Melnick J. L., Rawls W. E. Investigation of plaque formation in chick embryo cells as a biological marker for distinguishing herpes virus type 2 from type 1. J Gen Virol. 1971 Jan;10(1):1–9. doi: 10.1099/0022-1317-10-1-1. [DOI] [PubMed] [Google Scholar]
  6. McKelvey E. M., Kwaan H. C. Cytosine arabinoside therapy for disseminated herpes zoster in a patient with IgG pyroglobulinemia. Blood. 1969 Nov;34(5):706–711. [PubMed] [Google Scholar]
  7. Person D. A., Sheridan P. J., Herrmann E. C. Sensitivity of Types 1 and 2 Herpes Simplex Virus to 5-Iodo-2'-Deoxyuridine and 9-beta-d-Arabinofuranosyladenine. Infect Immun. 1970 Dec;2(6):815–820. doi: 10.1128/iai.2.6.815-820.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. RAPP F. INHIBITION BY METABOLIC ANALOGUES OF PLAQUE FORMATION BY HERPES ZOSTER AND HERPES SIMPLEX VIRUSES. J Immunol. 1964 Oct;93:643–648. [PubMed] [Google Scholar]
  9. Stubbs K. G., Snider M. E., Alford C. A., Jr Influence of host cell on biologic markers of types 1 and 2. Herpesvirus hominis. J Infect Dis. 1971 Feb;123(2):169–177. doi: 10.1093/infdis/123.2.169. [DOI] [PubMed] [Google Scholar]
  10. UNDERWOOD G. E., WISNER C. A., WEED S. D. CYTOSINE ARABINOSIDE (CA) AND OTHER NUCLEOSIDES IN HERPES VIRUS INFECTIONS. Arch Ophthalmol. 1964 Oct;72:505–512. doi: 10.1001/archopht.1964.00970020505014. [DOI] [PubMed] [Google Scholar]
  11. Walker W. E., Waisbren B. A., Martins R. R., Batayias G. E. In vitro determinations of viral susceptibility to drugs for possible clinical use. Antimicrob Agents Chemother (Bethesda) 1970;10:380–384. doi: 10.1128/AAC.10.2.380. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES